Marbocare 20 mg/ml Solution for Injection for Cattle and Pigs

Main information

  • Trade name:
  • Marbocare 20 mg/ml Solution for Injection for Cattle and Pigs
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Marbocare 20 mg/ml Solution for Injection for Cattle and Pigs
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Cattle, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0409/001
  • Authorization date:
  • 26-09-2012
  • EU code:
  • UK/V/0409/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2012

AN:01044/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Marbocare20mg/mlsolutionforinjectionforcattleandpigs(UK,IE,FR)

Odimar20mg/mlsolutionforinjectionforcattleandpigs(BE,NL,LU,ES,PT,DE,AT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance:

Marbofloxacin 20.0mg

Excipients:

Metacresol 2.0mg

Monothioglycerol 0.5mg

Disodiumedetate 0.1mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection

Clearyellowishsolution.

4. CLINICALPARTICULARS

4.1Targetspecies

-Cattle:pre-ruminantsupto100kgb.w.

-Pigs

4.2Indicationsforuse,specifyingthetargetspecies

Pre-ruminantcalves:

TreatmentofrespiratoryinfectionscausedbysensitivestrainsofPasteurellamultocida,

MannheimiahaemolyticaandMycoplasmabovis.

Pigs:

TreatmentofrespiratoryinfectionscausedbysensitivestrainsofActinobacillus

pleuropneumoniae,MycoplasmahyopneumoniaeandPasteurellamultocida.

4.3Contraindications

Donotuseinanimalswithknownhypersensitivitytomarbofloxacinortoanyother

quinoloneortoanyoftheexcipients.

Issued:December2012

AN:01044/2011

Page2of6

Donotuseincaseswherethepathogeninvolvedisresistanttootherfluoroquinolones

(crossresistance).

4.4Specialwarnings

None.

4.5Specialprecautionsforuse

(i) Specialprecautionsforuseinanimals

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhentheproductis

used.Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhich

haverespondedpoorly,orareexpectedtorespondpoorly,tootherclassesof

antimicrobials.Wheneverpossible,fluoroquinolonesshouldonlybeusedbasedon

susceptibilitytesting.Useoftheproductdeviatingfromtheinstructionsgiveninthe

SPCmayincreasetheprevalenceofbacteriaresistanttothefluoroquinolonesandmay

decreasetheeffectivenessoftreatmentwithotherquinolonesduetothepotentialfor

crossresistance.

(ii)Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidanycontact

withtheproduct.

Iftheproductcomesintocontactwiththeskinoreyes,rinsewithlargeamountsof

water.

Avoidaccidentalself-injection,sincethiscancauselocalirritation.

Washhandsafteruse.

Incaseofaccidentalself-injectionoringestion,seekmedicaladviceimmediately

andshowpackageleafletorthelabeltothephysician.

4.6Adversereactions(frequencyandseriousness)

Intramuscularorsubcutaneousinjectionsarewelltoleratedalthoughtheymaycause

transitorypainfulswellingswithoutclinicalimpact.

Administrationbytheintramuscularroutemaycausetransientlocalreactionssuchas

painandswellingattheinjectionsiteandinflammatorylesionswhichmaypersistfor6

daysinpigsandfor12daysincattle.

4.7Useduringpregnancy,lactationorlay

Marbofloxacinmaybeusedinpregnantandlactatingsows.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9Amountstobeadministeredandadministrationroute

Issued:December2012

AN:01044/2011

Page3of6

Toensureadministrationofthecorrectdose,bodyweightshouldbedeterminedas

accuratelyaspossible,toavoidunderdosing.

Therecommendeddosageis2mg/kgbodyweight/day(1ml/10kgBW)incattleand

pigs.

Thesingledailydoseforcalvesshouldbeadministeredbysubcutaneousor

intramuscularinjection,for3-5days.Thefirstinjectionmayalsobegivenbythe

intravenousroute.

Thesingledailydoseforpigsshouldbeadministeredbyintramuscularinjection,for3-5

days.

Thevolumeofinjectionshouldbelimitedto10mlateachsiteofinjectionforpigs.

Inordertoreducetheriskofparticulatecontaminationoftheproduct,itisrecommended

thatadraw-offneedlebeusedtoreducethenumberoftimestheseptumispunctured.

Donotbroachthe100mL-vialmorethan25timesanda250mL-vialmorethan50times

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Nosevereside-effectsaretobeexpectedatdosesupto5timestherecommended

doseincattleandpigs.

Overdosagemaycauseacutesignsintheformofneurologicaldisorderswhichshould

betreatedsymptomatically.

4.11Withdrawalperiod(s)

MEATAND

OFFAL

Pre-ruminatingcalves(upto

100kgbodyweight) 6days

Pigs 4days

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Fluoroquinolones

ATCVetCode:QJ01MA93

5.1Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothefluoroquinolone

group.ItactsbyinhibitionofDNAgyraseandshowsconcentrationdependant

Issued:December2012

AN:01044/2011

Page4of6

bactericidalactivity.Ithasabroad-spectrumactivityagainstGram-positivebacteriaand

Gram-negativebacteria(e.g.Pasteurellamultocida,Mannheimiahaemolyticaand

Actinobacilluspleuropneumoniae)aswellasagainstmycoplasmas(Mycoplasma

bovisandMycoplasmahyopneumoniae).

Themarbofloxacininvitroactivityagainstpathogensisolatedin2004frombovine

respiratorydiseasesduringaclinicalfieldtrialinFrance,Germany,SpainandBelgium,

isgood:MICvaluesarecomprisedbetween0.015and0.25µg/mlforM.haemolytica

(MIC

=0.124µg/ml;MIC

=0.025µg/ml)andbetween0.004and0.12µg/mlforP.

multocida(MIC

=0.022µg/ml;MIC

=0.009µg/ml). StrainswithaMIC≤1µg/mlare

sensitivetomarbofloxacinwhereasstrainswithaMIC≥4µg/mlareresistantto

marbofloxacin.

Resistancetofluoroquinolonesoccursmostlybychromosomalmutationwiththree

mechanisms:decreaseofthebacterialwallpermeability,expressionofeffluxpumpor

mutationofenzymesresponsibleformoleculebinding.

5.2Pharmacokineticparticulars

Aftersubcutaneousadministrationincattleandpigsattherecommendeddoseof2

mg/kgbodyweight,marbofloxacinisreadilyabsorbedanditsbioavailabilityiscloseto

100%.Itisweaklyboundtoplasmaproteins(lessthan10%inpigsand30%incattle),

extensivelydistributedandinmosttissues(liver,kidney,skin,lung,bladder,uterus

digestivetract)itachieveshigherconcentrationsthaninplasma.

Incattle,marbofloxaciniseliminatedslowlyinpre- ruminatingcalves(t1/2β=5-9h)

predominantlyintheactiveforminurine(3/4)andfaeces(1/4).

Inpigs,marbofloxaciniseliminatedslowly(t1/2β=8-10h)predominantlyintheactive

forminurine(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Disodiumedetate

Metacresol

Monothioglycerol

Gluconolactone

Mannitol

Waterforinjections

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Issued:December2012

AN:01044/2011

Page5of6

Shelflifeafterfirstopeningtheimmediatepackaging(20,50,100,250mlvials):28

days.The10mlvialsmustbeusedimmediatelyafterthefirstopening.

6.4.Specialprecautionsforstorage

Keepthecontainerintheoutercartoninordertoprotectfromlight.

10mlvials:Followingwithdrawaloftherequireddose,theremaindertothecontentsof

thevialshouldbediscarded.

6.5Natureandcompositionofimmediatepackaging

PackagedinAmbertypeIIglassvialsof10,20,50ml100and250ml.

Thevialsareclosedwithafluorinatedbromobutylrubberstopperandoversealedwith

analuminiumcap.

Eachvialispackagedinacardboardbox.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

AnimalcareLtd

CommonRoad

Dunnington

York

YO195RU

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm10347/4034

9. DATEOFFIRSTAUTHORISATION

19December2012

10.DATEOFREVISIONOFTHETEXT

December2012

Issued:December2012

AN:01044/2011

Page6of6

Approved: 19/12/2012

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

20-11-2018

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

22-6-2018

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

9-11-2011

Danish Pharmacovigilance Update, 20 October 2011

Danish Pharmacovigilance Update, 20 October 2011

In this edition of Danish Pharmacovigilance Update, you can read about: Use of medicines involving a risk of serious and life-threatening skin reactions, the European Medicines Agency to investigate the possible connection between orlistat and rare cases of severe liver toxicity, and the EMA’s review of peritoneal dialysis solutions from Baxter A/S.

Danish Medicines Agency

26-11-2018

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

FDA - U.S. Food and Drug Administration

4-9-2018

Agenda:  Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda: Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda of CHMP written procedure*20-23 August 2018

Europe - EMA - European Medicines Agency

22-8-2018

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye:  http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz . pic.twitter.com/ecJErFeiSH

FDA - U.S. Food and Drug Administration

20-7-2018

Agenda:  Agenda - CAT agenda of the 18-20 July 2018 meeting

Agenda: Agenda - CAT agenda of the 18-20 July 2018 meeting

Committee for Advanced Therapies (CAT) agenda for the meeting on 18-20 July 2018

Europe - EMA - European Medicines Agency

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration

20-6-2018

Rhiniseng (Laboratorios Hipra, S.A.)

Rhiniseng (Laboratorios Hipra, S.A.)

Rhiniseng (Active substance: inactivated vaccine against atrophic rhinitis in pigs) - Centralised - Yearly update - Commission Decision (2018)3952 of Wed, 20 Jun 2018

Europe -DG Health and Food Safety